Welcome to our dedicated page for Cardiocomm Solut news (Ticker: EKGGF), a resource for investors and traders seeking the latest updates and insights on Cardiocomm Solut stock.
The EKGGF news page tracks disclosures and developments related to CardioComm Solutions, Inc., which describes itself as a global medical provider of consumer heart monitoring and medical electrocardiogram (ECG) software and hardware solutions. Company news releases highlight its focus on remote patient monitoring (RPM), ECG management technologies, and the commercialization of its GEMS software platforms.
Readers can review updates on CardioComm’s product and technology milestones, such as Health Canada clearance for its GEMS Rhythm AI ECG interpretation software and the evolution of its GEMS FLEX, Holter, and long-term continuous monitoring (LTCM) platforms. News also covers initiatives like the Body-by-GEMS multiple bio-signal monitoring program and the GEMS C2M2 prototype for the Canadian Space Agency’s Connected Care Medical Module, aimed at supporting health management in remote or isolated environments.
Company announcements provide insight into partnerships and distribution arrangements, including integration of CardioComm’s ECG technology into Sony’s mSafety wearable platform and an exclusivity agreement in Quebec for distribution of TZ Medical ECG monitoring devices integrated with GEMS. Financing and capital structure news, such as insider loan facilities, royalty-based financing, and shares-for-debt settlements, offer additional context for investors following EKGGF.
By reviewing this news stream, investors and observers can see how CardioComm describes the progress of its ECG software, home and clinical devices, remote monitoring services, and funding activities that support the development and commercialization of its flagship ECG platforms.
CardioComm Solutions, Inc. (TSXV: EKG) has secured exclusive distribution rights in Quebec for TZ Medical Inc.'s ECG monitoring devices. This agreement enhances access to long-term continuous ECG monitoring devices for Canadians. The deal focuses on the Trident Pro and Trident Nano devices, which are integrated with CardioComm's Global Electrocardiogram Management software (GEMS™).
CardioComm plans to integrate these devices with new software releases, GEMS™ Holter and GEMS Long Term Continuous Monitoring, scheduled for 2025. This integration aims to meet the growing demand for combined 14 to 30-day Holter and Event monitoring. The exclusive rights in Quebec will facilitate hardware tendering processes with provincial hospitals using or considering GEMS™.
CardioComm Solutions (TSXV: EKG), a global provider of consumer heart monitoring and medical ECG software solutions, has entered into a revolving line-of-credit loan agreement with a company controlled by director Daniel Grima. The loan provides additional funding of up to $500,000, with an 8% annual interest rate and a repayment deadline of July 22, 2026. The loan is secured against the company's assets and can be repaid without penalty. The lender has the option to convert the loan into common shares at the TSX Venture Exchange's "discounted market price."
Additionally, CardioComm has issued 125,000 stock options to CEO Etienne Grima, exercisable at $0.05 per share for five years, vesting immediately. Both transactions are subject to regulatory approvals and securities laws.
Daniel Grima has acquired a total of 29,526,146 common shares of CardioComm Solutions (EKGGF) through debt settlement agreements.
Grima personally received 27,442,571 shares at $0.01 per share for settling $274,425.71 owed by the company. Additionally, his holding company, Xemxija Holdings, acquired 2,083,575 shares at $0.01 per share for settling $20,835.75 of debt.
Before the transaction, Grima held 6,910,555 shares (4.57% of the company). Post-transaction, he holds 36,436,702 shares, representing 18.87% of the total.
Grima's acquisition is for investment purposes, and he may adjust his holdings based on circumstances. The detailed disclosure can be reviewed on SEDAR+.
CardioComm Solutions, a provider of ECG software solutions, has completed its debt settlement transactions with certain creditors. To settle a total debt of $419,093.68, the company issued 41,909,368 common shares at $0.01 per share. These shares are subject to a four-month hold period, expiring on November 10, 2024. The transactions include related party dealings, as company directors participated in the settlements. However, these transactions are exempt from formal valuation and minority shareholder approval requirements under Multilateral Instrument 61-101, as they do not exceed 25% of the company's market capitalization.
CardioComm Solutions has announced an update regarding its debt settlement transactions with certain creditors. The company plans to issue 41,909,368 common shares at $0.01 per share to settle an aggregate debt of $419,093.68. This includes $318,786.12 owed to non-arm's length parties, settled through the issuance of 31,878,612 shares. The debt includes $44,360.41 in company expenses covered by non-arm's length parties. The issued shares will be subject to a four-month hold period and require approval from the TSX Venture Exchange. Transactions with company directors are classified as 'related party transactions' but are exempt from certain requirements under Multilateral Instrument 61-101.
CardioComm Solutions announced plans to settle $418,340.10 in outstanding debt by issuing 41,834,010 common shares at a deemed price of $0.01 per share. This transaction will retire $345,261.46 in structured debt and $73,078.64 in operational debt. The issuance of shares is pending TSX Venture Exchange approval and will be subject to a four-month hold period. Additionally, some transactions involve directors and are considered 'related party transactions' under Multilateral Instrument 61-101, but they are exempt from formal valuation and minority shareholder approval due to their fair market value being below 25% of the company's market capitalization.
Summary not available.
Summary not available.
Summary not available.
Summary not available.